Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.7.49 extracted from

  • Lee, W.G.; Frey, K.M.; Gallardo-Macias, R.; Spasov, K.A.; Chan, A.H.; Anderson, K.S.; Jorgensen, W.L.
    Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase (2015), Bioorg. Med. Chem. Lett., 25, 4824-4827.
    View publication on PubMedView publication on EuropePMC
Search for more literature for 2.7.7.49

Crystallization (Commentary)

Crystallization (Comment) Organism
molecular modeling of complexes with inhibitors, e.g. 6-([2-[(4-cyanophenyl)amino]pyrimidin-4-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile, 6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile Human immunodeficiency virus 1

Inhibitors

Inhibitors Comment Organism Structure
6-([2-[(4-cyanophenyl)amino]pyrimidin-4-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile compound has potency below 10 nM towards wild-type HIV-1 and viral variants containing the clinically important Y181C and K103N/Y181C mutations, greater activity than efavirenz particularly towards the K103N-bearing variant, normal cytotoxicity, and solubility Human immunodeficiency virus 1
6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile compound has potency below 10 nM towards wild-type HIV-1 and viral variants containing the clinically important Y181C and K103N/Y181C mutations, greater activity than efavirenz particularly towards the K103N-bearing variant, normal cytotoxicity, and solubility Human immunodeficiency virus 1

Organism

Organism UniProt Comment Textmining
Human immunodeficiency virus 1
-
-
-